Abstract
Control of sea lice, L epeophtheirus salmonis , on farmed A tlantic salmon, S almo salar , relies heavily on chemotherapeutants. However, reduced efficacy of many treatments and need for integrated sea lice management plans require innovative strategies. Resistance to emamectin benzoate (EMB), a major sea lice parasiticide, has been linked with P‐glycoprotein (P‐gp) expression. We hypothesized that host immunostimulation would complement EMB treatment outcome. Lepeophtheirus salmonis ‐infected Atlantic salmon were fed immunostimulatory or control feeds. Sea lice were collected for 24‐h EMB bioassays 1 and 2 weeks prior to commencement of EMB treatment of the fish. Two weeks after cessation of immunostimulant‐treated feed, EMB was administered at 150 μg kg −1 fish biomass for 7 days. The bioassay revealed stage, gender and immunostimulant‐related differences in EMB EC 50 . Sea lice attached to salmon with a history of immunostimulation exhibited significantly greater survival than those on control feeds, despite similar levels of EMB in host tissues. Lepeophtheirus salmonis from salmon with a history of immunostimulation also exhibited higher P‐gp mRNA expression as well as greater survivability compared to controls. Administration of immunostimulants prior to EMB treatment caused increased expression of P‐gp mRNA which could have consequently caused decreased efficacy of the parasiticide.